George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
It’s easy to be spooked by last weeks drop. Certainly some uncertainty about the weeks ahead.
However, rich individuals would not chance their arm on an AIM stock unless they saw something quite special.
It cannot be coincidence that they invest in Sareum whilst the world awaits a treatment for ARDS.
That’s only my opinion. God save the Queen.
Love peace and harmony.
Those who bought pre 737 clinical deal, saw it rise to 1.2p then slowly fade away to the lows of 0.3p.
Well we believed the science then, held on, and got our rewards for doing so.
And we bought more when we could afford to.
Now we have a few more molecules in the playing area, one going to be tried against Covid.
So…relax, we’ve been there and wore the t-shirt.
Good luck. TGIF!
Love peace and harmony
The power of numbers. Germatria is something worth studying. Ancient folk drew a rhombus of dimensions 10*5*6*5 which equals 26 and is revered as symbolically mean jvhv, or the name for god. Take that rhombus and divide it correctly and you may find numbers relating to pythagoras (some will be factors) and you can even find the angles of the great pyramid of Giza.
You will find this ancient symbol in many many places. Our ancient fathers trying to pass down their knowledge.
Personally any number adding to 3,6 or 9 is good.
I’d quite happily bail out at £1.08 per share.
Love peace and harmony.
My thoughts are that at the end of November we will know whether our tyk2 saves lives, and before that we will know , hopefully, how much in pre orders there are for our pill.
Before that there is a house in visoko…..
Got to say Thoth2, you deserve the adulation. Not only here, but mtfb board you got it spot on. Mainly addicted drug users needed their drug and based upon the likelihood that they wouldn’t have medical insurance (USA) it wasn’t a mass market. Much kudos.
Love peace and harmony.
Could be a case of getting as much as possible in p1 , whilst the covid play takes on its 100 day fast track. Nothing in preclinical so the value overall increases. The selection for tyk2 cancer is great , needed and in a huge multi billion dollar playing area.
Could be other things. All said there is nothing negative coming from Sareum.
Love peace and harmony.
DMT is a wonder drug. If only every head of state could take it and then set out their policies after, then possibly we could live in a more loving world.
However, governments seem to think they own your consciousness, so ban such drugs, the rest is sheep bleating.
Back to our drug, still pinching myself that we are invested in a company that has a molecule that downregulates the cykotine storm. That alone is a massive statement.
This 5m private funding detail is mightily interesting.
Ohm shante shante shante
Love peace and harmony.
Hey stealy,
The “vaccine” doesn’t work like a normal vaccine whereby they introduce a small dose of virus so the body can fight it and produce antibodies against it.
The “vaccines” send your body on high alert in hope it’s enough if you get covid symptoms then the body is kind of used to it.
Love peace and harmony.
Dare it be said Num4, that you are probably spot on with your assessment?
Base line of 9p per status quo, on nowt really, other than we are better than dexa, as good as barc, and we’ve got two wealthy individuals who have invested and boosted Sareum bottom line.
That’s just the covid play. We invested on the strength on early pre clinical results versus drugs being bought and put into humans.
Got to stop spending profit that doesn’t materially exist is a concern of mine, however it’s a great time to celebrate my wife’s 50th soon :)
Love peace and harmony.
There’s a plot of land in visoko , high up in wooded mountains for just a tad over £100k , needs plumbing and work doing. Within walking distance of the Bosnian pyramid of the sun, who always welcome volunteers.
That’s my little dream.
Num4 wants 15p to retire and sincerely hope he gets it.
Love peace and harmony.
When Dr Parker and his wife bought some shares at about 0.95p, it kept us investors happy, then it went south, all the way to around 0.3p. We got unhappy , then got glad as the price moved up.
Then the price went down, then we had the long termers , stating they were ok with the current price as they held an average of 0.73p.
Then COVID happened.
Personally , a 1000% increase , could never be scoffed.
However, covid is here and my thought are we have AGILE confirmation coming soon enough.
The rest is history.
Love peace and harmony.
On a Saturday night. Reading the posts on here has become a bit like Lord of the Flies.
What do you call two birds stuck together? Velcrows.
My daughter has recently tried courting; advised her that if the guy doesn’t like her fruity jokes, then just the mango.
Anyway, patience can be wearing thin. We can be spending the money before we have it. Always have in your mind love peace and harmony. Keep thinking BIG with Sareum, there are not many companies out there blessed as we are in this current silent war.
Love peace and harmony.
Hey Thoth2,
Excuse my apathy. The patents mentioned , are they the WO ones near the beginning of the end?
These two guys worked on the forerunner to Tyk2; IRAK1.
It’s an amazing time to be invested in this company.
Love peace and harmony.
Sareum intends to progress SDC-1802 into preclinical development (and pending satisfactory progress) into human clinical trials which could begin in 2020. The Company owns the commercialisation rights for these candidates and other dual TYK2/JAK1 inhibitors with profiles optimised for oncology indications.
Sareum announced on 10 September 2018 that it is also advancing SDC-1801 as a distinct dual TYK2/JAK1 inhibitor for the potential treatment of autoimmune diseases, including psoriasis, rheumatoid arthritis, inflammatory bowel disease and lupus. SDC-1802 also has the potential to act as a back-up molecule for these autoimmune indications.
Dr Tim Mitchell, CEO of Sareum, commented: "We are very pleased to have formally selected lead candidates from our TYK2 inhibitor programme for both cancer and autoimmune diseases. The candidates are distinct small molecules with attractive and highly competitive profiles for development in their respective indications. Both candidates have produced exciting results in preclinical disease models and we believe present valuable opportunities for licensing and/or further development. Our focus is now to advance both candidates into clinical studies, which we anticipate beginning in 2020."
From the September 2018 RNS. Pre-Covid of course.
Some estimates on here of 28p a share based on the above info. Pre-Covid of course.
Come on the Sareum! Ha!
Love peace and harmony.
In line with our business model, we continue to engage with potential partners with a view to securing commercial licences when they reach late preclinical or early clinical stages.
Taken from the final results RNS June 2019.
Today’s slides say they are seeking commercial licenses from early-mid clinical stage.
That’s a good advancement and they must be confident.
Love peace and harmony.